Drug Profile
OX 914
Alternative Names: OX914Latest Information Update: 09 Mar 2012
Price :
$50
*
At a glance
- Originator Orexo
- Class Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Seasonal allergic rhinitis
Most Recent Events
- 06 Mar 2012 Discontinued - Phase-II for Seasonal allergic rhinitis in Sweden (PO)
- 06 Mar 2012 Discontinued - Preclinical for Asthma in Sweden (PO)
- 06 Mar 2012 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Sweden (PO)